Business
Kali-Extracts $5 Million CBD Extraction Contract Could Grow Into $20 Million Through Mobile Extraction Lab Capacity
Kali-Extracts $5 Million CBD Extraction Contract Could Grow Into $20 Million Through Mobile Extraction Lab Capacity.
About this update from North American Cannabis Holdings, Inc.
[{"type":"text","content":"\nDALLAS, June 06, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced a presentation scheduled next week on Tuesday, June 11th were management will present KALY’s mobile cannabis extraction capacity to be utilized in its recently announced contract with a New York State Licensed Hemp Cultivation Operation anticipated to generate an estimated $5 million in revenue for KALY.  The presentation will include details on how the mobile cannabis extraction capacity will be utilized to potentially expand the $5 million contract into potentially more than $20 million in similar contracts.\n KALY owns and operates a U.S. Patented Cannabis Extraction Process.  In addition to its direct cannabis extraction business, the company is advancing biotechnology research for the future production of cannabis extract centric pharmaceuticals and at the same time, the company is currently generating revenue from the sale of CBD infused consumer products.  KALY is primarily a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas.  In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB).  In NCMB’s four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process.  The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity.  KALY has a deep pipeline of cannabinoid product candidates including four distinct compounds.  KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy. KALY is not relying on its biopharmaceutical development strategy alone to insure the company’s long-term success.  With the popularity of cannabis extracts for infusion into various consumer products, KALY’s patented extraction process offers arguably...